1612 GMT - Philips's cautious outlook for this year doesn't surprise after the company posted only slight order intake growth in 2024, ING analysts say in a note. The Dutch medical-device company's order intake grew 2% in the fourth quarter, bringing the annual growth rate to 1%, they say. With that in mind, it's unsurprising that the guidance for 1%-3% organic growth, including continued decline in China in 2025, was also a little weaker than expected, the analysts say. Divisionally, Philips posted a large adjusted Ebita shortfall in its core Diagnosis & Treatment division, offset by better-than-expected results in Connected Care, as the unit is recovering from its Respironics sleep apnea machines recall. Shares are down 12% at 23.81 euros.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 19, 2025 11:12 ET (16:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。